Seasonal shift in epidemics of respiratory syncytial virus infection in Japan

Miyama, Takeshi; Iritani, Nobuhiro; Nishio, Takayuki; Ukai, Tomohiko; Satsuki, Yuka; Miyata, Hiromi; Shintani, Ayumi; Hiroi, Satoshi; Motomura, Kazushi; Kobayashi, Kazuo

doi:10.1017/s0950268821000340

Cited by 26 publications

(16 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This seasonality distribution was consistent with previous estimates for the period up to 2016, in which cases typically began in autumn. 21,22 https://doi.org/10.2147/CEOR.S382495…”

Section: Data Source and Study Designmentioning

confidence: 99%

The Long-Term Healthcare Utilization and Economic Burden of RSV Infection in Children ≤5 Years in Japan: Propensity Score Matched Cohort Study

Chirikov¹,

Botteman²,

Simões³

2022

CEOR

View full text Add to dashboard Cite

The objective of this study was to estimate the long-term healthcare utilization and cost burden of RSV by chronological age of diagnosis (Year 1, Year 2 and Years 3-5 cohorts) as well as by gestational age at birth in Japan. Methods:The JMDC database was used to retrospectively identify RSV and control patients between February 1, 2011 and January 31, 2016 and follow them through December 31, 2017. Infants with RSV infection (n = 9028 in Year 1; n = 4929 in Year 2; n = 2004 in Years 3-5) were matched to controls (n = 17,886; n = 9351; n = 3655, respectively) based on gestational age and year and quarter of birth; controls were assigned the index date (ie, diagnosis) of their respective match. Covariate-balancing propensity score weights were employed adjusting for remaining imbalances between cohorts. The main outcomes were average cumulative rates for all-cause, asthma/wheezing, and respiratory-related hospitalizations, physician and urgent care/emergency visits and associated costs (reported as 2018 ¥JPY) over 36-months of follow-up since index. Results: Healthcare utilization was significantly higher among RSV cases for most comparisons. All-cause average differential cost burden was higher for RSV, compared to controls, among the following cohorts: Year 1 full-term (¥277,727); Year 2 preterm (¥530,302), late preterm (¥270,797), full-term (¥238,832); Years 3-5 preterm (¥110,057), late preterm (¥486,670), full-term (¥289,986). While all-cause costs were similar for preterm and late preterm children in the Year 1 cohort, respiratory-and asthma/ wheezing-related attributable costs were substantially higher for RSV. Conclusion: RSV infection had a significant long-term health and economic burden among children infected during their first year of life and later in life. Study findings have import for prevention strategies, currently directed at maternal immunization and monoclonal antibodies for preventing primary RSV infections in the first six months of life and beyond but also for older age not targeted currently.

show abstract

“…This seasonality distribution was consistent with previous estimates for the period up to 2016, in which cases typically began in autumn. 21,22 https://doi.org/10.2147/CEOR.S382495…”

Section: Data Source and Study Designmentioning

confidence: 99%

The Long-Term Healthcare Utilization and Economic Burden of RSV Infection in Children ≤5 Years in Japan: Propensity Score Matched Cohort Study

Chirikov¹,

Botteman²,

Simões³

2022

CEOR

View full text Add to dashboard Cite

show abstract

“…In fact, prior research predicted a spike in Tokyo RSV cases following the pandemic, though in reality it happened earlier than expected [ 9 ]. Notably, the seasonality of RSV has been shifting to earlier months over the past several years, and the pandemic may have accelerated this trend [ 10 ]. Similar resurgences in enteric pathogens have been observed in China after nonpharmaceutical interventions were relaxed [ 11 ].…”

mentioning

confidence: 99%

Decreased incidence followed by comeback of pediatric infections during the COVID-19 pandemic in Japan

et al. 2022

View full text Add to dashboard Cite

“…Peaks of infection have recently shown to change from fall and winter to summer and fall. 7 These seasonal outbreaks are a common cause of hospitalization in infants. [8][9][10] A large RSV surveillance study conducted in Japan from 2008 to 2015 showed that, excluding the 2009/2010 season, the number of reported RSV infections in young children increased every year, a result of a true increase, increased testing, or both.…”

Section: Introductionmentioning

confidence: 99%

“…In Japan, RSV activity fluctuates seasonally. Peaks of infection have recently shown to change from fall and winter to summer and fall 7 . These seasonal outbreaks are a common cause of hospitalization in infants 8–10 .…”

Section: Introductionmentioning

confidence: 99%

A phase I study to evaluate safety, pharmacokinetics, and pharmacodynamics of respiratory syncytial virus neutralizing monoclonal antibody MK‐1654 in healthy Japanese adults

Orito

Otani

Matsumoto

et al. 2022

Clinical Translational Sci

View full text Add to dashboard Cite

Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infection among all infants worldwide and remains a significant cause of morbidity and mortality. To address this unmet medical need, MK-1654, a half-life extended RSV neutralizing monoclonal antibody, is in clinical development for the prevention of RSV disease in infants. This was a phase I, randomized, placebocontrolled, single-site, double-blind trial of MK-1654 in 44 healthy Japanese adults. The safety, tolerability, pharmacokinetics, antidrug antibodies (ADAs), and serum neutralizing antibody (SNA) titers against RSV were evaluated for 1 year after a single intramuscular (i.m.) or intravenous (i.v.) dose of MK-1654 or placebo in five groups (100 mg i.m., 300 mg i.m., 300 mg i.v., 1000 mg i.v., or placebo). MK-1654 was generally well-tolerated in Japanese adults. There were no serious drug-related adverse events (AEs) reported in any MK-1654 recipient and no discontinuations due to any AEs in the study. The half-life of MK-1654 ranged from 76 to 91 days across dosing groups. Estimated bioavailability was 86% for 100 mg i.m. and 77% for 300 mg i.m. One participant out of 33 (3.0%) developed detectable ADA with no apparent associated AEs. The RSV SNA titers increased in a dose-dependent manner among participants who received MK-1654. These data support the development of MK-1654 for use in Japanese infants. How to cite this article: Orito Y, Otani N, Matsumoto Y, et al. A phase I study to evaluate safety, pharmacokinetics, and pharmacodynamics of respiratory syncytial virus neutralizing monoclonal antibody MK-1654 in healthy Japanese adults.

show abstract

Seasonal shift in epidemics of respiratory syncytial virus infection in Japan

Cited by 26 publications

References 4 publications

The Long-Term Healthcare Utilization and Economic Burden of RSV Infection in Children ≤5 Years in Japan: Propensity Score Matched Cohort Study

The Long-Term Healthcare Utilization and Economic Burden of RSV Infection in Children ≤5 Years in Japan: Propensity Score Matched Cohort Study

Decreased incidence followed by comeback of pediatric infections during the COVID-19 pandemic in Japan

A phase I study to evaluate safety, pharmacokinetics, and pharmacodynamics of respiratory syncytial virus neutralizing monoclonal antibody MK‐1654 in healthy Japanese adults

Contact Info

Product

Resources

About